At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Ablation +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
In Brief
A clinical study evaluating Ablation and Surgical Resection for Lung Cancer. Completed, enrolled 15 participants across 4 sites in 2 countries.
Detailed Summary
Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesGermany, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionMar 2017
Study CompletionNov 2017
TodayJul 2026
First PostedDec 24, 2014
Enrollment StartJan 1, 2015
Primary CompletionMar 13, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.5 years ago
Interventions
Ablationdevice
Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
Surgical Resectionprocedure
The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.